Search
Nemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigational[L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis. … [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]
Categories: Agents for Dermatitis, Excluding CorticosteroidsSerdexmethylphenidate
go.drugbank.com/drugs/DB16629Approved[A230698, A230708] Serdexmethylphenidate is a prodrug of the CNS stimulant [dexmethylphenidate], a common first-line treatment for ADHD, that is combined with [dexmethylphenidate] to provide extended plasma … [A230698, A230703] The underlying cause of ADHD is unclear but likely involves dysfunction in dopaminergic and noradrenergic neurotransmission, as evidenced by the clear beneficial effect of CNS stimulants
Categories: Psychostimulants, Agents Used for ADHD and NootropicsDDP-200
go.drugbank.com/drugs/DB05919ExperimentalDDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia
Taurochenodeoxycholic acid
go.drugbank.com/drugs/DB08833ExperimentalIt is also being investigated for its role in inflammation and cancer therapy. … Taurochenodeoxycholic acid is an experimental drug that is normally produced in the liver. Its physiologic function is to emulsify lipids such as cholesterol in the bile.
Categories: Compounds used in a research, industrial, or household settingAlectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalApproved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance … It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC
CX-717
go.drugbank.com/drugs/DB05047IllicitInvestigationalCX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.
Ancestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawnAncestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes. … It is a 166 amino acid protein produced by E. coli with an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal
Respiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigational[L46347] On May 3, 2023, it was approved by the FDA for immunization against lower respiratory tract disease (LRTD) as the first respiratory syncytial virus (RSV) vaccine approved in the United States … [L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380]
Bordetella pertussis toxoid antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14388ApprovedInvestigationalBordetella pertussis toxoid antigen (formaldehyde inactivated) is a vaccine.
Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, , Suspension for InjectionModafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalThe exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular … Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy.
Categories: Psychostimulants, Agents Used for ADHD and Nootropics